Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with Regorafenib and Cetuximab in Advanced Colorectal Cancer
NCT04745130Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in colorectal cancer (CRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04745130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745130.